- Home
- STNG vs IMVT Comparison
STNG vs IMVT Comparison
Compare STNG & IMVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STNG
- IMVT
- Stock Information
- Founded
- STNG 2009
- IMVT 2018
- Country
- STNG Monaco
- IMVT United States
- Employees
- STNG N/A
- IMVT N/A
- Industry
- STNG Marine Transportation
- IMVT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- STNG Consumer Discretionary
- IMVT Health Care
- Exchange
- STNG Nasdaq
- IMVT Nasdaq
- Market Cap
- STNG 3.1B
- IMVT 2.7B
- IPO Year
- STNG 2010
- IMVT N/A
- Fundamental
- Price
- STNG $53.98
- IMVT $16.00
- Analyst Decision
- STNG Strong Buy
- IMVT Buy
- Analyst Count
- STNG 4
- IMVT 10
- Target Price
- STNG $60.50
- IMVT $33.38
- AVG Volume (30 Days)
- STNG 939.8K
- IMVT 1.7M
- Earning Date
- STNG 10-28-2025
- IMVT 11-06-2025
- Dividend Yield
- STNG 2.94%
- IMVT N/A
- EPS Growth
- STNG N/A
- IMVT N/A
- EPS
- STNG 7.37
- IMVT N/A
- Revenue
- STNG $916,164,000.00
- IMVT N/A
- Revenue This Year
- STNG N/A
- IMVT N/A
- Revenue Next Year
- STNG $2.28
- IMVT N/A
- P/E Ratio
- STNG $7.64
- IMVT N/A
- Revenue Growth
- STNG N/A
- IMVT N/A
- 52 Week Low
- STNG $30.63
- IMVT $12.72
- 52 Week High
- STNG $73.62
- IMVT $32.10
- Technical
- Relative Strength Index (RSI)
- STNG 43.72
- IMVT 50.79
- Support Level
- STNG $55.33
- IMVT $15.81
- Resistance Level
- STNG $57.54
- IMVT $17.15
- Average True Range (ATR)
- STNG 1.47
- IMVT 0.73
- MACD
- STNG -0.82
- IMVT 0.10
- Stochastic Oscillator
- STNG 24.05
- IMVT 57.98
About STNG Scorpio Tankers Inc.
Scorpio Tankers Inc is a provider of marine transportation of petroleum products. It owned, lease financed, or chartered in vessels spanning three different vessel segments Handymax, MR, and LR2. The company's fleet of tankers is the eco-friendly, and newest fleet on the water hauling clean petroleum products. It provides seaborne transportation of crude oil and refined petroleum products. The company generates the majority of its revenue from LR2.
About IMVT Immunovant Inc.
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.